The Patent Finder

Idorsia Pharmaceuticals Ltd.

66 patents currently held · Updated Nov 17, 2026
28 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jul 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Azaindole Acetic Acid Derivatives and Their Use as Prostaglandin D2 Receptor Modulators (US 10,301,309) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 3 fees due Dec 20 to 27, 2026 · next Dec 20
  • 3 fees due Feb 1 to 28, 2027 · next Feb 1
  • 2 fees due Apr 6 to 17, 2027 · next Apr 6
  • 2 fees due Jun 12 to 15, 2027 · next Jun 12
  • 2 fees due Aug 6 to 23, 2027 · next Aug 6

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 19, 2026
  • 1 term has ended since Aug 19, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 7,763,638Substituted 1,2,3,4-Tetrahydroisoquinoline Derivatives
In force
 · High confidence
In forceHigh confidence
US 8,324,2324-Pyrimidinesulfamide Derivative
In force
 · High confidence
In forceHigh confidence
US 8,889,688Piperazines as Antimalarial Agents
In force
 · High confidence
In forceHigh confidence
US 9,000,029Proline Sulfonamide Derivatives as Orexin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 9,211,279Proline Sulfonamide Derivatives as Orexin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 8,895,606Proline Sulfonamide Derivatives as Orexin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 9,150,5662-(1,2,3-Triazol-2-YL)BENZAMIDE and 3-(1,2,3-Triazol-2-YL)PICOLINAMIDE Derivatives as Orexin Receptor Antagonists
In force
 · High confidence
In forceHigh confidence
US 9,266,8764-(Benzoimidazol-2-yl)-thiazole Compounds and Related Aza Derivatives
In force
 · High confidence
In forceHigh confidence
US 9,732,075Benzimidazole-Proline Derivatives
In force
 · High confidence
In forceHigh confidence
US 10,329,287Benzimidazole-Proline Derivatives
In force
 · High confidence
In forceHigh confidence
10 of 66 patents shown.
Pro members see all 66.
Pro members: see all 66 patents
Also on record, not counted in the 66: 28 patents in force now held by others · 82 lapsed for an unpaid fee · 4 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

15 pending · 5 abandoned · 7 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited